Jul 24, 2015 at 21:50 | Source: PTI
Drug major Sun Pharmaceutical's open offer to acquire 28.16 percent stake in Zenotech Laboratories elicited tepid response from the shareholders.
Jul 24, 2015 at 15:46 | Source: CNBC-TV18
In an interview with CNBC-TV18s Sonia Shenoy & Latha Venkatesh, Praful Bohra, VP- Research, Religare said that Lupins numbers are weak due to decline in the US business.
Jul 24, 2015 at 14:02 | Source: CNBC-TV18
Pharma Analyst Surajit Pal is not very keen on holding pharma biggies, given the newsflows that are associated with them. Lupin first quarter earnings have been disappointing and Pal believes the pain is going to continue for two-three months. Another big-ticket stock Sun Pharma too have seen a steep fall after it issued profit warning.
Jul 23, 2015 at 12:10 | Source: CNBC-TV18
Kunj Bansal of Centrum Wealth Management is of the view that Sun Pharmaceutical Industries is a good long term buy.
Jul 23, 2015 at 10:16 | Source: CNBC-TV18
Watch the interview of Kunj Bansal of Centrum Wealth Management with Latha Venkatesh & Sonia Shenoy on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.
Jul 21, 2015 at 16:25 | Source: CNBC-TV18
Despite the fall in Sun Pharma on the back of Monday's profit warnings, Parag Thakkar of HDFC Securities and Devang Mehta of Anand Rathi Financial Services advise investors to buy the stock and understand that the integration with Ranbaxy will take its own time. From a 18-24 months perspective, it is a great buy, says Mehta.
Jul 21, 2015 at 15:55 | Source: CNBC-TV18
Devang Mehta of Anand Rathi Financial Services recommends accumulating Sun Pharmaceutical Industries with a view of 18-24 months.
Jul 21, 2015 at 09:23 | Source: CNBC-TV18
Dipan Mehta and Prakash Diwan do not think Sun Pharma is currently a great investment.
Jul 21, 2015 at 09:07 | Source: CNBC-TV18
The Dilip Shanghvi-run company said yesterday its revenue in fiscal 2016 would be flat at best as it incurs further one-time costs to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
Jul 20, 2015 at 22:08 | Source: CNBC-TV18
Supply disruptions from Sun Pharma's Halol facility are also expected to continue for some more time. But the company did not give any timeline for the resolution of its issues with the USFDA. It said it is focusing on building backup supply for critical products.